CompletedNCT00294008
One-year review and two-year follow-up of long-acting risperidone treatment
About this title
Read the official source —Observational studyAges 18+Schizophrenia
Understand this study
Who was this study for?
Listed age limits: from 18 years.
Study information
Study start dateDecember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 230
- Sponsor
- Janssen Korea, Ltd., Korea
- Sponsor type
- Other organization
- Study type
- Observational
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Not clearly listed
- Age range
- Over 18 Years
- Official registry ID
- NCT00294008
- Official title
Show the full official title
Electronic Schizophrenia Treatment Adherence Registry(e-STAR): An Observational, International Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Janssen Korea, Ltd., Korea.
Did this study involve medication?
Yes. The study involved medication, including Risperdal Consta.
Who was this study for?
Listed age limits: from 18 years.
